Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Personalis Inc (NQ: PSNL )

1.930 -0.010 (-0.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Personalis Inc

< Previous 1 2 3 4 Next >
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
From Personalis, Inc.
Via Business Wire
Analyst Ratings for Personalis
 
Via Benzinga
Recap: Personalis Q1 Earnings
 
Via Benzinga
Personalis Reports First Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
From Personalis, Inc.
Via Business Wire
Personalis's Return On Capital Employed Insights
 
Via Benzinga
Earnings Outlook For Personalis
 
Via Benzinga
Personalis to Announce First Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
From Personalis, Inc.
Via Business Wire
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
From Personalis, Inc.
Via Business Wire
Cancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its Workforce
 
Via Benzinga
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
From Personalis, Inc.
Via Business Wire
Personalis Appoints Christopher Hall as Chief Executive Officer
From Personalis, Inc.
Via Business Wire
Toll Brothers To Rally 25%? Here Are 10 Other Analyst Forecasts For Friday
Oppenheimer boosted the price target for Universal Display Corporation (NASDAQ: OLED) from $150 to $160. Oppenheimer analyst Martin Yang maintained an Outperform rating on the stock. Universal Display... 
Via Benzinga
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down
 
Via Benzinga
Why Personalis Shares Are Trading Higher Today
 
Via Benzinga
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
From Personalis, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
 
Via Benzinga
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
From Personalis, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 152 stocks made new 52-week lows. 
Via Benzinga
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Personalis Announces CEO Retirement and Transition
From Personalis, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.